Impact of obesity on cyclosporine levels in nephrotic syndrome patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates how obesity affects the therapeutic response and safety of cyclosporine in patients with nephrotic syndrome. It involves recruiting 74 participants from Alexandria University Hospital, who will be divided into two groups: obese patients with a BMI over 25 kg/m2 and non-obese patients with a BMI under 25 kg/m2. Both groups will receive cyclosporine, but the obese group will have their doses adjusted based on their weight to achieve optimal therapeutic levels. The study will monitor blood and urine samples over a three-month period to assess treatment efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Obese and overweight Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (BMI\>25 kg/m2)
* Normal or underweight individuals Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (serving as control group)

Exclusion Criteria:

* Hepatic patients liver cirrhosis (moderate to severe liver impairment)
* Cancer patients,
* Pregnant and lactating female patients

Where it's running

• Alexandria University
  Alexandria, Egypt Recruiting

Study contacts

• Study coordinator: Enas A Mohamed, PharmD
• Email: gs-enas.elkady@alexu.edu.eg
• Phone: 01004344021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines

  This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.

  Recruiting at 2 sites St. James's Hospital, Ireland · Dublin and 1 other locations · NCT07561957

• SGLT2 inhibitors added to standard care in adult primary nephrotic syndrome

  This trial tests whether adding dapagliflozin or empagliflozin to standard treatment helps reduce protein in urine for adults with primary nephrotic syndrome.

  Recruiting Phase 2/3 Mansoura University · Al Mansurah, Dakahlia Governorate · NCT07214818

• Atacicept for multiple autoimmune glomerular diseases

  This will test whether weekly injections of atacicept can lower protein in the urine and help preserve kidney function in people aged 10 and older with IgA nephropathy, primary membranous nephropathy, or nephrotic syndromes such as MCD and FSGS.

  Recruiting Phase 2 Vera Therapeutics, Inc. · Brisbane, California · NCT06983028

• Multitarget approach for primary podocytopathies

  This project will test whether a lab cell culture can find a factor in the blood that causes proteinuria in people with primary podocytopathies and whether a combined therapy can block that factor in vitro.

  Recruiting at 2 sites Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan and 1 other locations · NCT06718894

• Follow-up on Rituximab treatment for children's nephrotic syndrome

  This study looks at how well rituximab works and its safety for children with hard-to-treat nephrotic syndrome by reviewing their past treatment data.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06530004

• Investigating the role of a protein in kidney damage related to nephrotic syndrome

  This study is trying to see if a protein called PCSK9 is linked to kidney damage and high cholesterol in people with nephrotic syndrome.

  Recruiting Kolding Sygehus · Kolding · NCT06373913

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.